



Xellia Pharmaceuticals Opens New Commercial Office in Dubai

Copenhagen, Denmark, 19 June 2020 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced the opening of a new commercial office in the Silicon Oasis, Dubai, UAE.

The new Xellia office will be used to support sales and representation in the area, strengthening Xellia's footprint and supply of anti-infectives in the Middle East and Africa (MEA) region.

This development will further expand Xellia's International Business Unit and responds to the increased demand from new customers in the region. Other markets where demand has been increasing includes China and Latin America. Xellia currently acts as a world-leading supplier of anti-infective products to more than 500 pharmaceutical companies in over 70 countries.

The regional expansion is also in line with the Company's aim to operate a global business model and vertical integration strategy. This ensures customers have access to both active pharmaceutical ingredients and finished dosage forms, whilst continuing to benefit from performance excellence and cost competitiveness.

Tamer Medhat, Senior Business Development and Sales Manager for Middle East and Africa, has been appointed to lead the new office.

Tamer Medhat, said: *"I'm very excited to have the opportunity to head up Xellia's new commercial office in Dubai, and to extend our efforts across the MEA region. I look forward to forming new relationships and strengthening bonds with existing customers in the area."*

Carl-Åke Carlsson, Xellia's CEO said: *"Xellia is well positioned for success in the MEA region, with a long history in development, manufacture and supply of critical anti-infective medicines against serious and often life-threatening infections. The opening of our new Dubai office is a further step in the evolution and growth of our international business, and will meet rising customer demand in the region. Our newly formed MEA team will allow us to better connect and serve our existing customers in this territory, and to explore new opportunities with potential partners."*

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Daniel Schwartzlose, President, International

Tel: +45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Siobhan Sanford

Tel: +44 (0) 7890 022 814 / +44 (0) 7534 247 411

Email: xellia@instinctif.com

Notes to Editors

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Further information about Xellia can be found at: www.xellia.com.